Quartz1d agobearish
Merck cuts 2026 profit forecast on Terns acquisition chargesThe pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
490last 24h
2474last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
The Wall Street Journal1d agobearish
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom LineMerck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.